ERGACAP

Main information

  • Trade name:
  • ERGACAP 20 CAP
  • Dosage:
  • 214MG
  • Pharmaceutical form:
  • CAP
  • Composition:
  • 20
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ERGACAP 20 CAP
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

24-4-2018

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Committee on Appropriations on FDA’s Fiscal Year 2019 budget

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Committee on Appropriations on FDA’s Fiscal Year 2019 budget

FDA Commissioner Scott Gottlieb, M.D. remarks to a U.S. Senate Subcommittee on Appropriations on the FDA’s Fiscal Year 2019 budget

FDA - U.S. Food and Drug Administration

21-4-2018

Giant Eagle Voluntarily Recalls Items Prepared with Romaine Lettuce Due to Potential E. coli Contamination

Giant Eagle Voluntarily Recalls Items Prepared with Romaine Lettuce Due to Potential E. coli Contamination

Giant Eagle, Inc. is recalling multiple items prepared with romaine lettuce and sold in its Giant Eagle, Market District and GetGo locations across western Pennsylvania, Ohio, West Virginia, Maryland and Indiana. This recall is in response to a CDC notice on romaine lettuce sourced by a supply partner from the Yuma, Arizona growing region.

FDA - U.S. Food and Drug Administration

8-3-2018

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations hearing “Examining U.S. Public Health Preparedness for and Response Effo

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations hearing “Examining U.S. Public Health Preparedness for and Response Effo

Commissioner remarks as prepared for testimony at the hearing “Examining U.S. Public Health Preparedness for and Response Efforts to Seasonal Influenza.”

FDA - U.S. Food and Drug Administration

7-12-2017

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. Senate Committee on Health, Education, Labor & Pensions Hearing, “Implementation of the 21st Century Cures Act: Progress and the Path Forward for Medical In

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. Senate Committee on Health, Education, Labor & Pensions Hearing, “Implementation of the 21st Century Cures Act: Progress and the Path Forward for Medical In

FDA Commissioner Gottlieb testifies before the U.S. Senate Committee on Health, Education, Labor & Pensions on the agency’s implementation of the 21st Century Cures Act

FDA - U.S. Food and Drug Administration

30-11-2017

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Implementing the 21st Century Cures Act: An Update from FDA and NIH"

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Implementing the 21st Century Cures Act: An Update from FDA and NIH"

FDA Commissioner Gottlieb provides testimony before the House Committee on Energy and Commerce on the agency’s implementation of the 21st Century Cures Act

FDA - U.S. Food and Drug Administration

25-10-2017

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives

Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives

FDA - U.S. Food and Drug Administration

24-10-2017

Pacific Coast Fruit Company Recalls Various Prepared Foods Vegetable Products Because of a Possible Health Risk

Pacific Coast Fruit Company Recalls Various Prepared Foods Vegetable Products Because of a Possible Health Risk

Pacific Coast Fruit Company in Portland, Oregon is voluntarily recalling multiple types of bagged processed salads based on the potential contamination of Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, Listeria infection can cause...

FDA - U.S. Food and Drug Administration

23-10-2017

Giant Eagle Voluntarily Recalls Breaded Shrimp Due to an Undeclared Egg Allergen

Giant Eagle Voluntarily Recalls Breaded Shrimp Due to an Undeclared Egg Allergen

All lot codes up to and including best by October 24, 2017 of Giant Eagle brand Breaded Shrimp, prepared and sold from the Prepared Foods grab and go sections inside Giant Eagle and Market District supermarkets through October 19, 2017 have been voluntarily recalled by Giant Eagle due to an undeclared egg allergen. People who have an allergy or severe sensitivity to egg run the risk of serious or life-threatening allergic reaction if they consume these products. The product is safe for consumption by tho...

FDA - U.S. Food and Drug Administration

11-9-2017

Hurricane Season: Be Prepared

Hurricane Season: Be Prepared

It's important to safeguard your food, water, and medicine before, during and after any severe weather event.

FDA - U.S. Food and Drug Administration

3-8-2017

FDA Drug Safety Communication: Update: Follow up to the Public Health Alert about Changes to the Heparin Sodium USP Monograph

FDA Drug Safety Communication: Update: Follow up to the Public Health Alert about Changes to the Heparin Sodium USP Monograph

Laboratory studies performed at the request of the U.S. Food and Drug Administration (FDA) have shown that Heparin Sodium, USP (heparin) made under the new United States Pharmacopeia (USP) Monograph ("new heparin") has approximately 10% less blood-thinning (anticoagulant) activity compared to heparin prepared using the previous ("old") USP Monograph.

FDA - U.S. Food and Drug Administration

21-6-2017

 Evaluation of a Danish meta-analysis of antidepressants

Evaluation of a Danish meta-analysis of antidepressants

The Danish Medicines Agency has evaluated a Danish meta-analysis made by the Copenhagen Trial Unit on the effects of antidepressants (SSRIs). The analysis attracted extensive media coverage. In connection with a consultation of the Danish Parliament’s Health and Senior Citizen's Committee, the Danish Medicines Agency has made a thorough evaluation of a Danish meta-analysis of antidepressants prepared by the Copenhagen Trial Unit (CTU). The CTU’s meta-analysis attracted considerable media coverage earlie...

Danish Medicines Agency

12-6-2017

Giant Eagle Voluntarily Recalls Select Items Due to an Undeclared Milk Allergen

Giant Eagle Voluntarily Recalls Select Items Due to an Undeclared Milk Allergen

Giant Eagle, Inc. has announced a voluntary recall of Market District Toasted Crumb Tilapia and Giant Eagle Toasted Crumb Tilapia sold fresh from the seafood department of its supermarkets, and Giant Eagle Breaded Chicken Breast sold in the prepared foods department, due to an undeclared milk allergen. People who have an allergy, or severe sensitivity to milk, may experience serious or life-threatening allergic reactions if they consume these products.

FDA - U.S. Food and Drug Administration

26-6-2015

Guide to individual case safety reporting

Guide to individual case safety reporting

We have prepared a guide to companies on the electronic reporting of adverse drug reactions (ADR) to the Danish Health and Medicines Authority.

Danish Medicines Agency

29-7-2014

Good laboratory practice in non-clinical trials

Good laboratory practice in non-clinical trials

Clinical Trials Facilitation Group (CTFG) has prepared a document describing the requirements as to good laboratory practice (GLP) in non-clinical trials.

Danish Medicines Agency

7-7-2014

Monitoring of medicines for births

Monitoring of medicines for births

The Danish Health and Medicines Authority has prepared a midterm review of the activities in the action plan for Danish regions' use of medicines for the induction of labour. The action plan was launched in the autumn of 2013 following a public debate about the use of these medicines, and it should be completed by the end of 2015.

Danish Medicines Agency

8-4-2014

Medicinal use of cannabis

Medicinal use of cannabis

The Danish Health and Medicines Authority has prepared a memo about the Danish experiences with and rules applicable to medicinal use of cannabis.

Danish Medicines Agency

26-1-2018

Scientific guideline:  Draft VICH GL57 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species, draft: consultati

Scientific guideline: Draft VICH GL57 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in food-producing species: marker residue depletion studies to establish product withdrawal periods in aquatic species, draft: consultati

This guidance is one of a series developed to facilitate the mutual acceptance of residue chemistry data for veterinary drugs used in food-producing animals by national/regional regulators. This guidance was prepared after consideration of the current national/regional requirements and recommendations for evaluating veterinary drug residues in the VICH regions.

Europe - EMA - European Medicines Agency

18-9-2017

Scientific guideline:  Draft guideline on data requirements for multi-strain dossiers 4 for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD) - Rev.1, draft: consultation open

Scientific guideline: Draft guideline on data requirements for multi-strain dossiers 4 for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD) - Rev.1, draft: consultation open

This guideline was first published in 2010 based on general scientific and regulatory principles in advance of much practical experience from assessing applications through European authorisation procedures. This revision was prepared following a review by CVMP of issues raised by stakeholders based on their experience of operating the guideline. Only minor changes were considered necessary to the guideline itself and an accompanying ‘Question and Answer’ document was produced to address the topics raise...

Europe - EMA - European Medicines Agency

18-9-2017

Scientific guideline:  Draft guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD) - Revision 1, draft: consultation open

Scientific guideline: Draft guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), bluetongue (BT) and foot-and-mouth disease (FMD) - Revision 1, draft: consultation open

This guideline was first published in 2010 based on general scientific and regulatory principles in advance of much practical experience from assessing applications through European authorisation procedures. This revision was prepared following a review by CVMP of issues raised by stakeholders based on their experience of operating the guideline. Only minor changes were considered necessary to the guideline itself and an accompanying ‘Question and Answer’ document was produced to address the topics raise...

Europe - EMA - European Medicines Agency